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ABSTRACT
Objective: The prevalence of invasive mycoses is increased in the immunocompromised patients with an increase in resistance developed against 
current antifungal drugs. This has led to the need for discovering novel combinations of the antifungal drugs to combat against resistant pathogenic spp. 
This study mainly targets to evaluate the antifungal activity of ibuprofen (IBU) alone and in combination with the standard antifungal drugs (polyenes 
and azoles) against eight isolates of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus niger.
Methods: The study was performed using the disc diffusion assay (DDA), microbroth dilution assay and spore germination inhibition assay. Moreover, 
cytotoxicity was checked by heamolytic assay.
Results: Minimum inhibitory concentration (MIC) of IBU against A. fumigatus and A. flavus using DDA is found to be in the range of 250-275 µg/disc 
while for A. niger isolates, the range was 500-575 µg/disc. Likewise, by broth microdilution assay and spore germination inhibitory assay, MIC 
determined, were in the range of 500-750 µg/ml against A. fumigatus and A. flavus while for A. niger, it was 1000-1500 μg/ml.
Conclusion: IBU demonstrated its antimycotic potential against all the eight isolates of Aspergillus spp. Moreover, preliminary combinatorial 
evaluation of IBU with the standard antifungal drugs reported by DDA revealed an increase in zone of inhibition as compared to the drugs alone. 
Further research regarding the confirmation of synergistic interaction between the selected drugs is in progress.
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INTRODUCTION
A prevalence of the opportunistic mycotic infections has varied for 
the past few decades. Invasive aspergillosis (IA), predominantly 
caused by Aspergillus fumigatus, followed by Aspergillus flavus 
and Aspergillus niger, have increased the risk of morbidity and 
mortality among immunosuppressed cases [1,2]. Although, for 
the past few decades, antimycotic agents such as polyenes, azoles, 
and echinocandins have proved to act significantly against IA [3,4]. 
However, the resistances against these standard antimycotic agents 
have developed the urge to search for the new drugs that can help 
eradicate severe opportunistic mycotic infections like IA. Moreover, 
lack of the effective monotherapy and the combination therapy of 
the standard drugs against IA has further allowed the researchers 
to develop new combinations that can lead to better therapeutic 
treatment for IA.
Ibuprofen (IBU) is a derivative of the propionic acid and relates to the 
class of non-steroidal anti-inflammatory drugs (NSAID), known for 
its anti-inflammatory, analgesic and anti-pyretic properties [5]. IBU 
inhibits the synthesis of prostaglandins from the arachidonic acid as 
it has the capability to obstruct the cyclo-oxygenase enzyme [5,6]. 
Earlier studies have demonstrated the antifungal activity of IBU and 
its synergy with the azoles against Candida spp. [7,8]. In addition, the 
IBU has also been reported to induce blocking of the efflux pumps 
such that reverting resistant Candida spp. into susceptible ones, 
against azoles [9,10].
Thus, in this study, antifungal activity of IBU has been evaluated alone 
and in combination with standard antifungal drugs, the polyenes: 
Amphotericin B (AmpB), nystatin (NYST) and the azoles: Ketoconazole 
(KETZ), flucanozole (FLUZ), via., various techniques against three 
clinical isolates of A. fumigatus, three of A. flavus and two clinical strains 
of A. niger.
METHODS
The antifungal drugs, AmpB, NYST, KETZ, and FLUZ obtained from 
Himedia Chemicals and IBU from the Fluka Analytical Chemicals. 
4 mg/ml AmpB and 10 mg/ml of IBU were taken as the stock solution 
and diluted with the distilled water to get the required concentration 
depending on the experiment done.
Pathogens
Pathogenic strains of A. fumigatus (clinical isolate 190/96 [Vallabhbhai 
Patel Chest Institute, Delhi (VPCI) and ITCC1634 [Indian Agricultural 
Research Institute Delhi (IARI)] and ITCC 4517 [IARI, Delhi]), A. flavus 
(clinical isolate 223/96 [VPCI, Delhi], ITCC 5192 [IARI, Delhi], and 
ITCC 5076 [IARI, Delhi]), and A. niger (clinical isolate 56/96 [VPCI, 
Delhi] and ITCC 5405 [IARI, Delhi]) were used in the current research. 
All the isolates were grown on sabouraud dextrose (SD) agar culture 
Petri plates of 10.0 cm diameter (tarsons) by inoculating with stock 
of A. fumigatus, A. flavus, and A. niger and incubating at 37°C in a 
biochemical-oxygen demand incubator. After 96 hrs incubation, spores 
were collected from culture plates and distributed evenly in phosphate 
buffer saline (PBS). The spores were collected and a concentration of 
108 spores/mL was used to perform the experiments.
Assay
The antimycotic activity of IBU was analyzed by the disc diffusion 
assay (DDA), microbroth dilution assay (MDA), and spore germination 
inhibition assays (SGIA) as illustrated previously [4,11].
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DDA
DDA was performed using the radiation sterilized Petri plates cultured 
with the SD agar and inoculated with 100 µl of homogenized suspension 
of 1×108 spores/ml of Aspergillus spp. Discs of 5.0 mm in diameter 
(Whatman filter paper No. 1) were placed on dried plates. Furthermore, 
discs were impregnated with the different concentrations of IBU in the 
range of 125-1000 μg/disc and AmpB within range of 5-0.35 µg/disc. 
After incubation at 37°C, Petri plates were observed at 24 and 48 hrs to 
check if there was any zone of inhibition, around the discs to know the 
antifungal effect.
MDA
The assay was executed in 96-well microtiter flat bottom plates 
(Tarson). Different dilutions of IBU starting with 1000 µg/ml 
were prepared in 100 µl of culture medium. Moreover, wells were 
administered with 10 µl of spores (1×108 spores/ml). 96-well plates 
were then incubated at 37°C and observed visually after 48 hrs. The 
well with no growth, i.e., complete inhibition of growth, was taken as 
end point and considered minimum inhibitory concentration (MIC).
SGIA
Different concentrations of IBU in 100 µl of culture medium were 
prepared in 96-well plates by double dilution method. Inoculation of 
each well was done with 10.0 µl of spore suspension containing 100 ± 
5 spores. After 16 hrs of incubation at 37°C, microtitre plates were 
assessed for germination of spores with an inverted microscope. The 
number of germinated and non-germinated spores will be counted. 
The percentage of inhibition of spore germination was calculated by 
the formula described by Ruhil et. al. [4]. The least concentration of 
the IBU, which was responsible for more than 90% inhibition of spore 
germination was taken as MIC90.
Toxicity studies
Haemolytic assay
This method [4,11] was performed using the erythrocytes from the 
healthy humans was taken and rinsed them with autoclaved PBS. 
Erythrocyte suspension (2.0% v/v) was prepared and exposed with IBU 
and AmpB starting with concentration of 1000 µg/ml at 37°C for 1 hr. The 
eppendorph tubes were allowed to centrifuge at 5000 rpm (rotation per 
minute) for 10 minutes. Optical density of the supernatant was calculated 
at 415 nm by spectrophotometer (Ultraviolet–visible Spect Lambda Bio 
20 Perkin-Elmer). Hemolysis done by the test compounds were measured 
in percentage and the concentration responsible for <10% hemolysis was 
considered non-toxic. PBS was used as the negative controls while triton 
X as positive controls along with the erythrocytes.
In vitro combinatorial evaluation
In vitro combinatorial evaluation (preliminary) among polyenes and 
azoles with NSAID IBU was performed using DDA. The 6 mm discs of 
Whatmann filter paper one were inoculated with 1.1 µg/disc of AmpB, 
NYST, KETZ, FLUZ, and MIC of KETZ and FLUZ, as calculated by DDA) 
alone and with 129 µg of IBU. Incubating the plates at 37°C for 48 hrs 
allowed the zone of inhibition to be visibly clear such that radius was 
measured after an interval of 24 and 48 hrs. No antifungal potential was 
declared where zone of inhibition was below 6 mm.
RESULTS AND DISCUSSION
In vitro antimycotic potential
The MIC of AmpB, KETZ, FLUZ, NYST by using DDA was 0.76, 6.24, 31.26, 
and 1.1 µg/disc, respectively, against all the eight pathogenic stains of 
Aspergillus genera. The mean of diamtere of zone of inhibition along 
with standard deviation was also measured for IBU as shown in Table 1.
Remarkably, IBU created an optically clear zone of inhibition of mycotic 
growth against all eight Aspergillus isolates. The geometric mean 
(GM) MIC of AmpB (standard antifungal), against three isolates of 
A. fumigatus, A. flavus and two of A. niger was 1.6 µg/ml, by MDA and 
SGIA. The GM of MIC of IBU has been summarized in Table 2.
The antifungal activity of IBU against the most pathogenic strain, 
i.e., A. fumigatus (VPCI190/96) was clearly noticeable with DDA, MDA, 
SGIA shown in Figs. 1-3. These outcomes established that IBU have 
natural activity against the Aspergillus spp.
The fungal isolates were observed to show disparity in their 
susceptibility when they were exposed with the IBU in different culture 
media. The culture media can influence the intensity of antimycotic 
activity [12]. Consequently, in vitro activity of the IBU against all the 
eight isolates of Apergillus spp were examined in three test media, 
i.e., RPMI 1640, potato dextrose broth (PD broth) and SD broth, 
concluded in Table 3.
Toxicity test
Complete lysis of erythrocytes is done by AmpB, NYST, KETZ at a 
concentration of 37.30, 67.2, and 124 µg/ml, respectively. However, IBU 
was non toxic >1 mg/ml (Fig. 4).
Combination study
The polyenes (AmpB and NYST), azoles (KETZ and FLUZ) alone and 
with IBU was infused on the discs; data have been summarized in 
Table 4 after calculating zone of inhibition.
The combination of IBU with FLUZ displayed no activity almost or very 
less potential while increased zone of inhibition reported maximum in 
a combination of IBU with polyenes and also has synergy with KETZ. 
Table 1: MIC determination of IBU by DDA
Drugs Mean of diameter of zone of inhibition
Pathogens Mean±SD (mm)
NSAID A.fumigatus (3)# A. niger (2)# A. flavus (3)#
IBU (µg/disc)
1000 11.5±0.1 10.4±0.2 11.3±0.2
500 8.9±0.2 7.3±0.3 8.8±0.1
250 6.8±0.1 NAP 6.7±0.2
125 NAP NAP NAP
AmpB
0.76 6.4±0.2 6.5±0.2 6.4±0.1
SD: Standard deivaiton, NAP: No antifungal potential, #Number of strains, 
NSAID: Non-steroidal anti-inflammatory drugs, IBU: Ibuprofen, MIC:, DDA: Disc 
diffusion assay, A. fumigatus: Aspergillus fumigatus, A. flavus: Aspergillus flavus, 
A. niger: Aspergillus niger, AmpB: Amphotericin B
Table 2: Summary of GM of MIC of IBU by different assays
Pathogens GM*MIC of IBU
MDA (µg/ml) DDA (µg/ml) SGIA (µg/ml)
A. fumigatus (3) 572.35 258.07 572.35
A. niger (2) 1224.74 536.19 1224.74
A. flavus (3) 572.35 258.07 572.35
*GM: Geomatric mean, MIC: Minimum inhibitory concentration, IBU: 
Ibuprofen, MDA: Microbroth dilution assay, DDA: Disc diffusion assay, 
SGIA: Spore germination inhibition assays, A. fumigatus: Aspergillus fumigatus, 
A. flavus: Aspergillus flavus, A. niger: Aspergillus niger
Table 3: In vitro activity of IBU in different test media
Pathogens GM MIC of IBU
SD broth PD broth RPMI 1640
A. fumigatus (3) 572.35 314.980 721.12
A. niger (2) 1224.74 1000 1732.05
A. flavus (3) 572.35 314.980 721.12
IBU: Ibuprofen, GM: Geometric mean, MIC: Minimum inhibitory 
concentration, A. fumigatus: Aspergillus fumigatus, A. flavus: Aspergillus flavus, 
A. niger: Aspergillus niger, PD broth: Potato dextrose broth
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These data suggest that IBU have positive interactions with polyenes 
and KETZ.
Our results clearly portrayed that NSAID can indisputably be 
administered as antimycotic agent to boost efficiency of current 
antimycotic drugs as IBU is non-toxic even at higher concentrations 
than standard antifungals so there cytotoxicity might get reduced while 
administered in combination.
CONCLUSION
Constant investigations for proficient prevention of IA have been 
in progress for the past few decades. As a result, alternative drugs 
whose antifungal properties are still unknown can be tested against 
pathogenic opportunistic mycotic agents such as IBU. Their interaction 
with the standard antifungal agents (polyenes and azoles) reduced 
the toxic effect associated with the current drug monotherapies while 
increasing their antimycotic activity. Our study displayed synergistic 
and effective interaction between NSAID IBU and polyenes (maximum). 
Further research regarding confirmation of synergistic interactions 
between the selected drugs is in progress.
Fig. 2: Disc diffusion assay of non-steroidal anti-inflammatory 
drugs (ibuprofen) against Aspergillus fumigatus (Vallabhbhai 
Patel Chest Institute, 190/96). A - 125 µg/disc, B – 250 µg/disc, 
C – 500 µg/disc, D - 1000 µg/disc
Fig. 3: Spore germination inhibition assays of ibuprofen against 
Aspergillus spp.
Fig. 4: Toxicity test of ibuprofen by heamolytic assay
Fig. 1: Microbroth dilution assay of ibuprofen against Aspergillus 
fumigatus (Vallabhbhai Patel Chest Institute, 190/96)
Table 4: In vitro combination of the standard drugs with IBU against the Aspergillus spp. by DDA
Drugs (µg/disc) Mean diameter zone of inhibition (mm)
Pathogens
A. fumigatus (3) A. niger (2) A. flavus (3)
24 hrs 48 hrs 24 hrs 48 hrs 24 hrs 48 hrs
AmpB (1.1) 7.3±0.1 7.2±0.2 6.8±0.2 6.5±0.1 7.3±0.1 7.2±0.2
NYST (1.1) 6.9±0.1 6.4±0.2 6.5±0.2 6.1±0.1 6.9±0.1 6.4±0.2
KETZ (6.24) 6.4±0.2 6.2±0.1 6.3±0.1 6.0±0.1 6.4±0.2 6.2±0.1
FLUZ (31.26) 6.2±0.2 6.0±0.2 6.1±0.1 NAP 6.2±0.2 6.0±0.2
IBU (129) NAP NAP NAP NAP NAP NAP
AmpB:IBU (1.1:129) 12.8±0.1 12.6±0.2 12.0±0.1 11.8±0.2 12.8±0.1 12.6±0.2
NYST:IBU (1.1:129) 7.8±0.1 7.6±0.2 7.3±0.1 7 2±0.1 7 8±0.1 7.6±0.2
KETZ:IBU (6.24:129) 7.0±0.2 6.8±0.3 6.9±0.1 7.1±0.1 7.0±0.2 6.8±0.3
FLUZ:IBU (31.26:129) 6.5±0.2 6.4±0.3 6.3±0.2 6.2±0.2 6.5±0.2 6.4±0.3
NAP: No antifungal potential, A. fumigatus: Aspergillus fumigatus, A. flavus: Aspergillus flavus, A. niger: Aspergillus niger, IBU: Ibuprofen, AmpB: Amphotericin B, 
NYST: Nystatin, KETZ: Ketoconazole, FLUZ: Flucanozole, DDA: Disc diffusion assay
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